Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes

References

• Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66(2):241–255. doi:10.2337/db16-0806
   PubMed Web of Science ®Google Scholar
• U.K. Prospective Diabetes Study group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249–1258. doi:10.2337/diab.44.11.1249
   PubMed Web of Science ®Google Scholar
• Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the insulin resistance atherosclerosis study. Diabetes. 2006;55(4):1114–1120. doi:10.2337/diabetes.55.04.06.db05-1100
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443. doi:10.1056/NEJMoa066224
   PubMed Web of Science ®Google Scholar
• Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care. 1992;15(3):442–455. doi:10.2337/diacare.15.3.442
   PubMedGoogle Scholar
• Yokoyama H, Oishi M, Takamura H, et al. Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40). BMJ Open Diabetes Res Care. 2016;4(1):e000294. doi:10.1136/bmjdrc-2016-000294
   PubMed Web of Science ®Google Scholar
• Franch-Nadal J, Roura-Olmeda P, Benito-Badorrey B, Rodriguez-Poncelas A, Coll-de-Tuero G, Mata-Cases M. Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration. Fam Pract. 2015;32(1):27–34. doi:10.1093/fampra/cmu048
   PubMedGoogle Scholar
• Hayashino Y, Izumi K, Okamura S, Nishimura R, Origasa H, Tajima N. Duration of diabetes and types of diabetes therapy in Japanese patients with type 2 diabetes: the Japan diabetes complication and its prevention prospective study 3 (JDCP study 3). J Diabetes Investig. 2017;8(2):243–249. doi:10.1111/jdi.12550
   PubMedGoogle Scholar
• Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80(4):1037–1044. doi:10.1172/JCI113157
   PubMed Web of Science ®Google Scholar
• Takahara M, Shiraiwa T, Katakami N, Matsuoka TA, Shimomura I. Marked recovery from glucotoxicity of beta-cell function after medical nutrition therapy without pharmacotherapy in type 2 diabetic outpatients with extreme hyperglycemia: a pilot retrospective study. Endocr J. 2017;64(11):1125–1129. doi:10.1507/endocrj.EJ17-0222
   PubMedGoogle Scholar
• Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468–475. doi:10.2337/dc16-0985
   PubMed Web of Science ®Google Scholar
• Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69–78. doi:10.2337/dc17-1414
   PubMed Web of Science ®Google Scholar
• Yamamoto-Honda R, Takahashi Y, Mori Y, et al. Changes in antidiabetic drug prescription and glycemic control trends in elderly patients with type 2 diabetes mellitus from 2005–2013: an analysis of the National Center Diabetes Database (NCDD-03). Intern Med. 2018;57(9):1229–1240. doi:10.2169/internalmedicine.9481-17
   PubMed Web of Science ®Google Scholar
• Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333–347. doi:10.1111/dom.12610
   PubMed Web of Science ®Google Scholar
• Namba M, Iwakura T, Nishimura R, et al. The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the Committee on a Survey of Severe Hypoglycemia in the Japan Diabetes Society. J Diabetes Investig. 2018;9(3):642–656. doi:10.1111/jdi.12790
   PubMedGoogle Scholar
• Ikeda Y, Kubo T, Oda E, Abe M, Tokita S. Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: retrospective diagnosis procedure combination database analysis. J Diabetes Investig. 2018;9(4):925–936.
   PubMedGoogle Scholar
• Inagaki N, Harashima SI, Iijima H. Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients. Expert Opin Pharmacother. 2018;19(8):895–908. doi:10.1080/14656566.2018.1473378
   PubMed Web of Science ®Google Scholar
• Yokote K, Terauchi Y, Nakamura I, Sugamori H. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opin Pharmacother. 2016;17(15):1995–2003. doi:10.1080/14656566.2016.1219341
   PubMed Web of Science ®Google Scholar
• Goda M, Yamakura T, Sasaki K, Tajima T, Ueno M. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan. Curr Med Res Opin. 2018;34(2):319–327. doi:10.1080/03007995.2017.1392293
   PubMed Web of Science ®Google Scholar
• Nakamura I, Maegawa H, Tobe K, Uno S. Safety and effectiveness of ipragliflozin for type 2 diabetes in Japan: 12-month interim results of the STELLA-LONG TERM post-marketing surveillance study. Adv Ther. 2019;36(4):923–949. doi:10.1007/s12325-019-0895-1
   PubMed Web of Science ®Google Scholar
• Ito Y, Van Schyndle J, Nishimura T, Sugitani T, Kimura T. Drug utilization patterns in patients with diabetes initiating sodium glucose co-transporter-2 inhibitors (SGLT2i) in Japan: a multi-database study (2014–2017). Diabetes Ther. 2019;10(6):2233–2249. doi:10.1007/s13300-019-00710-2
   PubMedGoogle Scholar
• Kaneto H, Obata A, Kimura T, et al. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic beta-cell function and reduction of insulin resistance. J Diabetes. 2017;9(3):219–225. doi:10.1111/1753-0407.12494
   PubMed Web of Science ®Google Scholar
• Kahn SE, Prigeon RI, McCullough DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for an hyperbolic function. Diabetes. 1993;42:1663–1667. doi:10.2337/diab.42.11.1663
   PubMed Web of Science ®Google Scholar
• Retnakaran R, Qi Y, Goran MI, Hamilton JK. Evaluation of proposed oral disposition index measures in relation to the actual disposition index. Diabet Med. 2009;26(12):1198–1203. doi:10.1111/j.1464-5491.2009.02841.x
   PubMedGoogle Scholar
• Takahara M, Shiraiwa T, Matsuoka TA, Katakami N, Shimomura I. Ameliorated pancreatic beta cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin. Endocr J. 2015;62(1):77–86. doi:10.1507/endocrj.EJ14-0335
   PubMedGoogle Scholar
• Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Investig. 2018;9(3):657–697.
   PubMed Web of Science ®Google Scholar
• Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–1470. doi:10.2337/diacare.22.9.1462
   PubMed Web of Science ®Google Scholar
• Sha S, Devineni D, Ghosh A, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014;9(9):e110069. doi:10.1371/journal.pone.0105638
   PubMed Web of Science ®Google Scholar
• Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24 week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother. 2014;15(11):1501–1515. doi:10.1517/14656566.2014.935764
   PubMed Web of Science ®Google Scholar
• Kohnert KD, Augstein P, Zander E, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care. 2009;32(6):1058–1062. doi:10.2337/dc08-1956
   PubMedGoogle Scholar
• Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in beta-cell function. Diabetes Care. 2014;37(4):1116–1123. doi:10.2337/dc13-2591
   PubMedGoogle Scholar
• Chen T, Xu F, Su JB, et al. Glycemic variability in relation to oral disposition index in the subjects with different stages of glucose tolerance. Diabetol Metab Syndr. 2013;5:38. doi:10.1186/1758-5996-5-38
   PubMedGoogle Scholar
• Matsuoka TA, Kaneto H, Kawashima S, et al. Preserving Mafa expression in diabetic islet beta-cells improves glycemic control in vivo. J Biol Chem. 2015;290(12):7647–7657.
   PubMedGoogle Scholar
• Shimo N, Matsuoka TA, Miyatsuka T, et al. Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key beta-cell factors under diabetic conditions. Biochem Biophys Res Commun. 2015;467(4):948–954. doi:10.1016/j.bbrc.2015.10.038
   PubMedGoogle Scholar
• Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33(6):1389–1394. doi:10.2337/dc09-2082
   PubMed Web of Science ®Google Scholar
• Kalra S, Mukherjee JJ, Venkataraman S, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab. 2013;17(5):819–834. doi:10.4103/2230-8210.117219
   PubMedGoogle Scholar
• Fujita Y, Inagaki N. Update on the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in Asians and non-Asians. J Diabetes Investig. 2019;10(6):1408–1410. doi:10.1111/jdi.13150
   PubMedGoogle Scholar